Publications by authors named "Keisa Takeda"
Purpose: In this follow-up of the R-NAC-01 study, we assessed the long-term oncological benefit of four courses of modified leucovorin, 5-fluorouracil (FU), and oxaliplatin (mFOLFOX6) chemotherapy before rectal surgery.
Methods: In this prospective, multicenter study (UMIN 000012559) involving 11 hospitals in Japan, patients with lower rectal cancer underwent four cycles of mFOLFOX6 chemotherapy and subsequent surgery within four to six weeks. The 3-year recurrence-free survival and local recurrence rates were then reported.
Article Synopsis
- The study aimed to evaluate the safety of rectal surgery following 5-fluorouracil-leucovorin-oxaliplatin chemotherapy (FOLFOX6) in rectal cancer patients.
- Conducted across 11 Japanese hospitals, the research included 41 patients who underwent chemotherapy before surgery, with results showing manageable postoperative complications and nerve preservation in most cases.
- The findings suggest that surgery after modified FOLFOX6 chemotherapy is a viable and safe option for patients with locally advanced rectal cancer, although no patients achieved complete pathological remission.
Obturator hernia (OH) is a rare condition that accounts for 0.073-1% of abdominal hernias and 0.48% of bowel obstructions.
View Article and Find Full Text PDFBackground: A Rho-ROCK signal system induces vascular contraction and neutrophil migration, both of which are characteristic features found with ischemia and reperfusion injury of the liver. We tested our hypothesis that a novel ROCK I inhibitor, Y-27632, attenuates hepatic ischemia and reperfusion injury.
Methods: Rats underwent 70% partial hepatic ischemia for 120 minutes and subsequent reperfusion.